Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Oncobiologics Inc    ONS

ONCOBIOLOGICS INC (ONS)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

ONCOBIOLOGICS, INC. : Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/09/2018 | 10:21pm CEST

Item 3.03 Material Modification to Rights of Security Holders.

On February 9, 2018, Oncobiologics, Inc. (the "Company") extended the expiration date of its outstanding Series A warrants (NASDAQ: ONSIW; CUSIP number 68235M 113) (the "Series A Warrants") to the earlier to occur of 5:00 p.m.New York City time on (a) the date that is twenty (20) business days after the date on which the closing sales price of the common stock is greater than or equal to $7.25 per share and (b) February 18, 2019, by entering into a second amendment to that certain Warrant Agreement dated as of May 18, 2016 by and between the Company and the American Stock Transfer & Trust Company, LLC, as warrant agent.

The Series A Warrants to purchase up to an aggregate of 3,333,333 shares of the Company's common stock, par value $0.01 per share, were originally issued as part of the units in the Company's May 2016 initial public offering and originally expired February 18, 2017. The Company previously extended the expiration date of the Series A Warrants from February 18, 2017 to February 18, 2018. The Series A Warrants have an exercise price of $6.60 per share and would otherwise have expired at 5:00 pmNew York City time on February 18, 2018. The expiration date has been extended to 5:00 p.m.New York City time on the earlier to occur of (a) the date that is twenty (20) business days after the date on which the closing sales price of the common stock is greater than or equal to $7.25 per share and (b) February 18, 2019.

The Series A Warrants and shares of common stock issuable upon exercise of the Series A Warrants are registered on Form S-1, as amended, previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). When required, the Company will amend or supplement the prospectus to reflect this expiration date extension for the Series A Warrants, which will be filed with the SEC, and mailed to the holders of record of the Series A Warrants.

The foregoing summary of the amendment to the Warrant Agreement is qualified in its entirety by reference to the complete text of such amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.



 Item 8.01 Other Information.




On February 9, 2018, the Company issued a press release with respect to the foregoing, which is filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.




(d)           Exhibits.

Exhibit No.                               Description
  10.1          Amendment #2 to the Warrant Agreement dated May 18, 2016 by and
              between Oncobiologics, Inc. and American Stock Transfer & Trust
              Company LLC, as Warrant Agent, dated February 9, 2018
  99.1          Press Release dated February 9, 2018

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONCOBIOLOGICS INC
08/14ONCOBIOLOGICS : Management's Discussion and Analysis of Financial Condition and ..
AQ
08/14ONCOBIOLOGICS, INC. : Results of Operations and Financial Condition, Financial S..
AQ
08/03ONCOBIOLOGICS, INC. : Change in Directors or Principal Officers, Other Events, F..
AQ
08/02ONCOBIOLOGICS : Appoints Lawrence A. Kenyon as President and CEO
AQ
07/20ONCOBIOLOGICS : Completes Exchange of Series A Convertible Preferred Stock for N..
AQ
07/19ONCOBIOLOGICS, INC. : Entry into a Material Definitive Agreement, Unregistered S..
AQ
07/19ONCOBIOLOGICS : Completes Exchange of Series A Convertible Preferred Stock for N..
AQ
07/13ONCOBIOLOGICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/12ONCOBIOLOGICS : Regains Compliance with Applicable Nasdaq Listing Requirements
AQ
07/06ONCOBIOLOGICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
News from SeekingAlpha
08/14Oncobiologics reports Q3 results 
05/15Oncobiologics misses by $0.09 
05/14Oncobiologics secures $15M capital raise; shares down 5% 
02/14Oncobiologics reports Q1 results 
01/29Premarket analyst action - healthcare 
Financials ($)
Chart ONCOBIOLOGICS INC
Duration : Period :
Oncobiologics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCOBIOLOGICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 79%
EPS Revisions
Managers
NameTitle
Lawrence A. Kenyon President, CEO, CFO & Director
Ralph H. Thurman Executive Chairman
Kenneth M. Bahrt Chief Medical Officer
Pankaj Mohan Director
Kurt J. Hilzinger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCOBIOLOGICS INC-33.85%27
CELLTRION, INC.--.--%29 145
IQVIA HOLDINGS INC22.78%24 472
LONZA GROUP18.34%23 390
INCYTE CORPORATION-29.40%14 126
SEATTLE GENETICS, INC.38.13%11 851